Hercules Capital, Inc. (HTGC)
| Previous Close | 19.30 |
| Open | 19.40 |
| Bid | 19.21 x 900 |
| Ask | 19.22 x 800 |
| Day's Range | 19.19 - 19.41 |
| 52 Week Range | 12.40 - 19.43 |
| Volume | |
| Avg. Volume | 931,318 |
| Market Cap | 3.13B |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | 8.36 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.92 (9.95%) |
| Ex-Dividend Date | May 13, 2024 |
| 1y Target Est | N/A |
- Business Wire
Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the First Quarter 2024
SAN MATEO, Calif., April 30, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a first quarter 2024 total cash distribution of $0.48 per share. The following shows the key dates of the first quarter 2024 dis
- PR Newswire
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, today announces it has entered into a $35m loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules").
- Business Wire
Hercules Capital Celebrates 20th Anniversary with $20.0 Billion in Cumulative Originations
SAN MATEO, Calif., April 24, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), is celebrating its 20th year of originations activity by reaching the $20.0 billion milestone in total debt commitments.
